共查询到18条相似文献,搜索用时 109 毫秒
1.
目的 观察慢性丙型肝炎(CHC)患者抗病毒治疗24周时外周血CD4+和CD8+T淋巴细胞(T细胞)表面表面程序性死亡1 (PD-1)和程序性死亡配体1(PD-L1)表达水平,分析其与抗病毒治疗临床转归的关系.方法 24例CHC患者,均采用聚乙二醇干扰素α-2a (Peg-IFN α-2a)每周皮下注射一次,联合利巴韦林800 ~ 1200 mg/d,治疗24 ~ 48周.采用流式细胞术和实时荧光定量检测患者治疗前、治疗4、12、24周外周血CD4+和CD8+T细胞表面PD-1、PD-L1表达水平和外周血HCV RNA,全自动生化分析仪检测ALT.采用SPSS16.0软件.两样本计量结果分析采用t检验,治疗前后的计量结果采用重复测量的单因素或两因素方差分析,所有检验为双侧检验. 结果 CHC患者治疗后4周HCV RNA阴性者19例,CD4+和CD8+T细胞表面PD-1的表达率在治疗前分别为18.6%±6.1%和16.6%±13.8%,治疗24周时分别为10.3%±7.7%和9.4%±4.6%,治疗前后比较,PD-1的表达明显下降,F值为12.406和4.955,P值为0.002和0.039,差异有统计学意义.CD8+T细胞表面PD-L1的表达率在治疗前为17.5%±13.7%,治疗4、12、24周时分别为25.9%±11.1%、29.6%±15.1%、32.0%±15.7%,治疗后明显升高,F值分别为9.063、8.365、9.736,P值均<0.01.治疗4周时,HCV RNA阳性者5例,仅发现CD8+T细胞表面PD-L1的表达治疗24周(39.2%±15.6%)与治疗前(17.4%±16.7%)比较明显升高,F=10.292,P=0.033.持续病毒学应答者20例:CD4+T细胞表面PD-1的表达在治疗4、12、24周分别为14.4%±7.5%、14.0%±6.9%、10.7%±7.6%,治疗前为20.2%±7.5%,与治疗前比较明显下降,F值分别为6.133、5.541、14.780,P<0.05或P<0.01.CD8+T细胞表面PD-1的表达在治疗12、24周分别为10.2%±4.6%和10.1%±4.9%,治疗前为16.8%±13.4%,治疗前后比较,PD-1的表达在治疗后明显下降,F值为4.964和4.613,P值均<0.05.CD8+T细胞表面PD-L1的表达在治疗12、24周分别为30.8%±16.6%和35.2%±16.5%,治疗前为19.0%±14.5%,治疗后明显升高,F=6.442,P=0.020和F=12.349,P=0.002.复发组4例,各治疗时间点PD-1和PD-L1与治疗前比较,差异无统计学意义.结论 快速有效的抗病毒治疗可以下调CHC患者外周血CD4+和CD8+T细胞表面PD-1的表达,上调CD8+T细胞表面PD-L1的表达.CHC患者外周血CD4+和CD8+T细胞表面PD-1和PD-L1表达水平的变化可能与患者抗病毒治疗临床转归存在关系. 相似文献
2.
3.
4.
背景:慢性乙型肝炎病毒(HBV)感染者T细胞表面程序性死亡受体1(PD-1)呈持续性高表达。然而关于抗病毒治疗前后慢性乙型肝炎(CHB)患者T细胞表面PD-1表达变化及其与病毒载量关系的报道较少。目的:动态观察CHB患者抗病毒治疗早期外周血CD4+和CD8+T细胞表面PD-1表达水平,探讨其表达与血清HBV DNA载量和丙氨酸氨基转移酶(ALT)水平之间的关系。方法:以流式细胞术分别检测31例CHB患者抗病毒治疗前或基线期(T1)、治疗后4~8周(他)和12.16周(T3)的外周血CD4^+和CD8^+T细胞表面PD-1表达水平,以实时荧光定量聚合酶链反应(PCR)检测血清HBV DNA载量,同时检测血清ALT水平。结果:抗病毒治疗早期,CHB患者外周血CD4^+和CD8^+T细胞表面PD.1表达水平逐渐下调(P〈0.05),血清HBV DNA载量和ALT水平亦逐步降低(P〈0.01);CD4^+和CD8^+T细胞表面PD-1表达与HBV DNA载量(P〈0.01)和ALT水平(P〈0.05)均呈正相关。结论:有效的抗病毒治疗可通过降低CHB患者的病毒载量使T细胞表面PD-1表达下调,T细胞表面PD-1表达水平与患者疾病状态密切相关。 相似文献
5.
目的 探讨慢性乙型肝炎患者在抗病毒治疗过程中程序性死亡分子1(PD-1)及其主要配体PD-L1表达的变化情况及其与HBeAg/抗-Hbe血清学转换的关系.方法 对10例人类白细胞抗原(HLA)-A2阳性的HBeAg阳性慢性乙型肝炎患者予以替比夫定抗病毒治疗24 周,分别于治疗的0、12周和24周随访,检测HBV DNA水平、外周血单个核细胞(PBMC)表面PD-1和PD-L1表达水平、HBV特异性T淋巴细胞数量与其表达PD 1水平,及PBMC体外培养上清液中干扰素(IFN)γ水平.其中HBV DNA定量采用荧光定量PCR法检测;PBMC自新鲜血分离,部分PBMC加入重组HBcAg体外培养7d,加入HBV抗原表位肽五聚体复合体;PD-1和PD-L1阳性细胞、CD8'T淋巴细胞以及CD8和PD-1双阳性细胞用流式细胞仪检测;IFN γ水平用酶联免疫吸附试验检测.比较不同时间点PBMC表面PD-1和PD L1表达水平、HBV特异性CD8'T淋巴细胞数量及其PD-1表达水平、PBMC培养上清液中IFN γ水平.对抗病毒治疗前后对应指标数值的变化采用配对t检验分析.结果 治疗前HBV DNA水平为5.16~8.77 log10拷贝/ml,治疗24周时,7例HBV DNA水平低于检测下限,3例仍可检测到,但明显低于基线水平.2例HBeAg/抗-Hbe血清学转换,2例HBeAg阴转,6例仍维持HBeAg阳性.0、12周和24周PBMC表面PD 1表达水平分别为52.1%±17.0%、39.1%±18.2%和23.4%±16.3%(24周和0周比较,P<0.01);PD-L1分别为45.6%±15.4%、34.6%±16.2%和20.9%±9.5%(24周和0周,P<0.01;24周和12周比较P<0.05);HBV特异性T淋巴细胞上PD-1表达水平分别为76.2%±10.4%、66.5%±15.4%和49.5%±25.3%(24周和0周比较,P<0.01;12周和0周比较,P<0.05;24周和12周比较,P<0.05);HBV特异性T淋巴细胞分别为1.3%±0.5%、1.5%±1.0%和2.2%±1.5%; IFN γ水平(pg/ml)分别为91.7±82.1、99.4+93.5和109.0+86.6.24周HBeAg/抗-Hbe血清学转换者上述指标变化明显大于无HBeAg/抗-Hbe血清学转换者.结论 直接抑制HBV复制能降低PD-1、PD-L1表达水平,并增加HBV特异性CD8'T淋巴细胞的数量和功能.早期PD-1快速下降和HBV特异性T淋巴细胞数量及功能的恢复与早期HBeAg/抗-Hbe血清学转换的关系有待于进一步研究. 相似文献
6.
目的 动态观察慢性乙型肝炎患者恩替卡韦抗病毒治疗后不同时期外周血T淋巴细胞(简称T细胞)表面程序性死亡受体1(PD-1)表达的变化,并探讨其与HBeAg血清学转换间的关系.方法 对20例HBeAg阳性慢性乙型肝炎患者予以恩替卡韦抗病毒治疗并随访51周,根据HBeAg是否发生血清学转换分为:HBeAg未转换组(14例),HBeAg转换组(6例).分别于治疗前(基线,T0)、治疗2~4周(T1)、治疗5~10周(T2)、治疗11~20周(T3)、治疗21~30周(T4)、治疗31~51周(T5)收集外周血,流式细胞术检测CD4+、CD8+T细胞表面PD-1的表达水平,实时荧光定量PCR检测血清HBV DNA载量,同时检测血清ALT水平.正态分布资料采用独立样本t检验,非正态分布者采用Mann-Whitney U检验比较组间差异,相关性分析采用Pearson相关分析.结果 治疗前两组患者血清HBV DNA载量分别为(7.54±0.67)log10拷贝/ml、(7.30±0.79)log10拷贝/ml(P>0.05),ALT水平为(187.26±184.15)U/L、(272.17±215.07)U/L(P>0.05),外周血CD4+T细胞表面PD-1表达水平为6.04%±3.71%6.77%±2.88%(P>0.05),CD8+T细胞表面PD-1表达水平为6.39%±3.33%、8.88%±2.84%(P>0.05).恩替卡韦抗病毒治疗后两组患者血清HBV DNA载量、ALT水平的下降与CD4+、CD8+T细胞表面PD-1表达的下调呈显著正相关(r=0.212,P=0.05;r=0.377,P<0.01;r=0.279,P<0.05;r=0.347,P<0.01).在相同的随访时间段内,HBeAg转换组血清HBV DNA载量、ALT水平及外周血CD4+、CD8+T细胞表面PD-1表达的下降率均高于HBeAg未转换组,且两组间△ T0~T1、△T0~T2期HBV DNA的下降率及△T0~T2、△T0~T3期CD8+T细胞表面PD-1表达的下降率差异有统计学意义(分别为49.9%对比37.3%,56.7%对比47.4%,70.1%对比-4.2%,66.9%对比24.5%,P值均<0.05).结论 HBeAg阳性慢性乙型肝炎患者经恩替卡韦抗病毒治疗后,外周血CD8+T细胞表面PD-1表达的快速下调与血清HBV DNA相似,可作为预测后期HBeAg血清学转换的指标之一.Abstract: Objective To observe longitudinally the expression of Programmed death 1 (PD-1) on peripheral blood T cells in chronic hepatitis B patients underwent antiviral treatment with entecavir (ETV)and to explore the relationship between PD-1 expression and HBeAg seroconversion.Methods Twenty HBeAg positive patients underwent antiviral treatment with ETV were followed up for 51 weels.14 patients remained HBeAg positive and 6 patients achieved HBeAg seroconversion.Peripheral blood was collected at six time points:T0:baseline,T1:2-4week;T2:5-10week;T3:11-20week;T4:21-30week:T5:31-51week.PD-1 expressions on T cells were assessed by flow cytometry.Serum HBV DNA loads were determined by real-time fluorescent quanttative polymerase chain reaction (PCR) and serum ALT levels were examined at the same time.Results At baseline,serum HBV DNA load of patients without HBeAg seroconversion and with HBeAg seroconversion were (7.54 ± 0.67) log10 copies/ml and (7.30 ± 0.79) log10 copies/ml(P > 0.05),the ALT levels were (187.26 ± 184.15) U/L and (272.17 ± 215.07) U/L (P > 0.05),PD-1 exprissions on CD4+ T cells were 6.04% ± 3.71% and 6.77% ± 2.88% (P > 0.05),PD-1 exprissions on CD8+ T cells were 6.39% ± 3.33% and 8.88% ± 2.84% (P > 0.05).After ETV treatment,serum HBV DNA loads and ALT levels both decreased gradually,which was positively correlated with PD-1 expressions on CD4+ and CD8+ T cells (r = 0.212,P = 0.05;r = 0.377,P < 0.01;r = 0.279,P < 0.05;r = 0.347,P < 0.01 ).During the same monitoring period,the HBV DNA loads,ALT levels and PD-1 expressions on T cells of the patients with HBeAg seroconversion decreased significantly as compared with the patients without HBeAg seroconversion.Besides,the decrease of HBV DNA loads during period △ T0-T1 and △ T0-T2 and PD-1 expressions on CD8+ T cells during period △ T0-T2 and △ T0-T3 were significantly different between these two kinds of patients (49.9% vs 37.3%,P < 0.05;56.7% vs 47.4%,P < 0.05;70.1% vs -4.2%,P < 0.05;66.9% vs 24.5%,P < 0.05).Conclusion The rapid decrease of PD-1 expression on peripheral CD8+ T cells after antiviral treatment with ETV is positvely correlated with the decrease of serum HBV DNA loads and may be used as a predictive index for HBeAg seroconversion in HBeAg positive patients. 相似文献
7.
目的 研究程序性死亡分子-1(PD-1)及其配体(PD-L1)表达水平与慢性HBV感染者HBV DNA水平的相关性及抗病毒治疗对其表达的影响.方法 检测137例慢性HBV感染者的外周血单个核细胞(PBMC)表面PD-1和PD-L1,并检测其中64例人类白细胞抗原(HLA)-A2阳性者HBV特异性CTL数量.ELlSA法检测PBMC体外培养上清液中IFN-γ浓度.比较10例HBeAg阳性慢性乙型肝炎(CHB)患者予替比夫定抗病毒治疗24周前后上述指标的变化.两组间均数比较采用两独立样本的t检验,多组间的差异采用单因素方差分析,相关分析采用Pearson相关分析.结果 HBV DNA<3 lg、3~6 lg和>6 lg拷贝/mL组问PBMC表面PD-1和PD-L1表达均明显高于健康对照组,但差异无统计学意义;3组HBV特异性CTL表面PD-1表达分别为(69.3±11.2)%、(76.5±9.1)%和(78.0±11.7)%,HBV DNA>6 lg拷贝/mL 组PD-1表达明显高于<3 lg拷贝/mL组,而HBV特异性CTL数量明显低于<3 lg拷贝/mL组;3组PBMC体外培养上清液中IFN-γ水平差异无统计学意义.HBeAg阳性组和阴性组间上述指标差异无统计学意义.替比夫定抗病毒治疗12周和24周时,PD-1、PD-L1表达较治疗前明显下降,伴有HBV特异性CTL数量逐渐增加和IFN-γ水平升高.结论 慢性HBV感染者PBMC表面PD-1的表达较健康者明显上调,且HBV特异性CTL表面表达PD-1水平与血清HBV DNA水平相关,但与HBeAg状态无关.抑制HBV复制能降低PD-1、PD-L1表达,并增加HBV特异性CTL的数量和功能.Abstract: Objective To study the relationship between programmed death-1 (PD-1)/programmed death-1 ligand (PD-L1) expressions and serum hepatitis B virus (HBV) DNA levels in chronic hepatitis B (CHB) patients. Methods A total of 137 CHB patients and 10 healthy controls were enrolled in the study. The peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood samples. HBV-specific cytotoxic T lymphocyte (CTL) was expanded in vitro in 64 human leucocyte antigen (HLA)-A2 positive patients. Flow cytometry was used to detect HLA-A2 type,expressions of PD-1/PD-L1 on PBMCs and PD-1 on HBV specific CTL. Interferon gamma (IFN-γ)was measured by commercial enzyme-linked immunosorbent assay (ELISA) kits. PD-1/PD-L1expressions on PBMCs, HBV-specific CTL and IFN-γ level in PBMC culture medium were compared among patients with different baseline HBV DNA levels. Ten hepatitis B e antigen (HBeAg) positive patients were treated with telbivudine for 24 weeks. The above mentioned parameters were determined and compared before and after the antiviral treatment. Independent-samples t test were used to compare means between two groups and one-way A NOVA were used to compare means among multigroups. We used the pearson corretation test to assess corretation significance. Results The PD-1 and PD-L1 expressions on PBMCs in patients with baseline HBV DNA<3 lg copy/mL, 3-6 lg copy/mL and >6 lg copy/mL were all significant higher than those in healthy control group, but no statistical differences were found. PD-1 expressions on HBV-specific CTL in the three CHB patient groups were (69.3±11.2)%, (76.5±9. 1)% and (78.0±11.7)%, respectively. However, PD-1 expression on HBV-specific CTL was higher, while the frequency of HBV-specific CTL cells was lower in HBV DNA >6 lg copy/mL group compared to HBV DNA<3 lg copy/mL group. The above parameters, including expressions of PD-1 and PD-L1, the frequency of HBV-specific CTL and its PD-1 expression were not significantly different between HBeAg-positive group and HBeAg-negative group. Compared with baseline, PD-1 and PD-L1 expression decreased obviously accompanying with increase of HBV-specific CTL cells frequency and IFN-γ level after 12 weeks and 24 weeks of telbivudine treatment. Conclusions PD-1 expression on HBV-specific CTL correlates with serum HBV DNA level, but not HBeAg status in CHB patients. Suppression of HBV replication can reduce PD-1/PD-L1 expressions and partially restore HBV specific CTL function. 相似文献
8.
Objective To study the relationship between programmed death-1 (PD-1)/programmed death-1 ligand (PD-L1) expressions and serum hepatitis B virus (HBV) DNA levels in chronic hepatitis B (CHB) patients. Methods A total of 137 CHB patients and 10 healthy controls were enrolled in the study. The peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood samples. HBV-specific cytotoxic T lymphocyte (CTL) was expanded in vitro in 64 human leucocyte antigen (HLA)-A2 positive patients. Flow cytometry was used to detect HLA-A2 type,expressions of PD-1/PD-L1 on PBMCs and PD-1 on HBV specific CTL. Interferon gamma (IFN-γ)was measured by commercial enzyme-linked immunosorbent assay (ELISA) kits. PD-1/PD-L1expressions on PBMCs, HBV-specific CTL and IFN-γ level in PBMC culture medium were compared among patients with different baseline HBV DNA levels. Ten hepatitis B e antigen (HBeAg) positive patients were treated with telbivudine for 24 weeks. The above mentioned parameters were determined and compared before and after the antiviral treatment. Independent-samples t test were used to compare means between two groups and one-way A NOVA were used to compare means among multigroups. We used the pearson corretation test to assess corretation significance. Results The PD-1 and PD-L1 expressions on PBMCs in patients with baseline HBV DNA<3 lg copy/mL, 3-6 lg copy/mL and >6 lg copy/mL were all significant higher than those in healthy control group, but no statistical differences were found. PD-1 expressions on HBV-specific CTL in the three CHB patient groups were (69.3±11.2)%, (76.5±9. 1)% and (78.0±11.7)%, respectively. However, PD-1 expression on HBV-specific CTL was higher, while the frequency of HBV-specific CTL cells was lower in HBV DNA >6 lg copy/mL group compared to HBV DNA<3 lg copy/mL group. The above parameters, including expressions of PD-1 and PD-L1, the frequency of HBV-specific CTL and its PD-1 expression were not significantly different between HBeAg-positive group and HBeAg-negative group. Compared with baseline, PD-1 and PD-L1 expression decreased obviously accompanying with increase of HBV-specific CTL cells frequency and IFN-γ level after 12 weeks and 24 weeks of telbivudine treatment. Conclusions PD-1 expression on HBV-specific CTL correlates with serum HBV DNA level, but not HBeAg status in CHB patients. Suppression of HBV replication can reduce PD-1/PD-L1 expressions and partially restore HBV specific CTL function. 相似文献
9.
Objective To study the relationship between programmed death-1 (PD-1)/programmed death-1 ligand (PD-L1) expressions and serum hepatitis B virus (HBV) DNA levels in chronic hepatitis B (CHB) patients. Methods A total of 137 CHB patients and 10 healthy controls were enrolled in the study. The peripheral blood mononuclear cells (PBMCs) were isolated from fresh blood samples. HBV-specific cytotoxic T lymphocyte (CTL) was expanded in vitro in 64 human leucocyte antigen (HLA)-A2 positive patients. Flow cytometry was used to detect HLA-A2 type,expressions of PD-1/PD-L1 on PBMCs and PD-1 on HBV specific CTL. Interferon gamma (IFN-γ)was measured by commercial enzyme-linked immunosorbent assay (ELISA) kits. PD-1/PD-L1expressions on PBMCs, HBV-specific CTL and IFN-γ level in PBMC culture medium were compared among patients with different baseline HBV DNA levels. Ten hepatitis B e antigen (HBeAg) positive patients were treated with telbivudine for 24 weeks. The above mentioned parameters were determined and compared before and after the antiviral treatment. Independent-samples t test were used to compare means between two groups and one-way A NOVA were used to compare means among multigroups. We used the pearson corretation test to assess corretation significance. Results The PD-1 and PD-L1 expressions on PBMCs in patients with baseline HBV DNA<3 lg copy/mL, 3-6 lg copy/mL and >6 lg copy/mL were all significant higher than those in healthy control group, but no statistical differences were found. PD-1 expressions on HBV-specific CTL in the three CHB patient groups were (69.3±11.2)%, (76.5±9. 1)% and (78.0±11.7)%, respectively. However, PD-1 expression on HBV-specific CTL was higher, while the frequency of HBV-specific CTL cells was lower in HBV DNA >6 lg copy/mL group compared to HBV DNA<3 lg copy/mL group. The above parameters, including expressions of PD-1 and PD-L1, the frequency of HBV-specific CTL and its PD-1 expression were not significantly different between HBeAg-positive group and HBeAg-negative group. Compared with baseline, PD-1 and PD-L1 expression decreased obviously accompanying with increase of HBV-specific CTL cells frequency and IFN-γ level after 12 weeks and 24 weeks of telbivudine treatment. Conclusions PD-1 expression on HBV-specific CTL correlates with serum HBV DNA level, but not HBeAg status in CHB patients. Suppression of HBV replication can reduce PD-1/PD-L1 expressions and partially restore HBV specific CTL function. 相似文献
10.
11.
慢性乙型肝炎是影响我国人群健康的主要疾病之一,HBV的慢性感染可导致疾病的进展。程序性死亡因子(PD)1是近年来发现的属于B7/CD28家族的重要协同刺激分子,与其配体(PD-L)结合后在调节T淋巴细胞的活化、分化及增殖功能方面起着重要作用。在慢性HBV感染的不同阶段,PD-1及其配体的表达存在差异。PD-1及其配体在不同的免疫细胞上的相互作用引起机体的免疫耐受,最终导致HBV感染的慢性化。通过不同途径阻断PD-1/PD-L通路可以使耗竭的T淋巴细胞功能得到改善,提示可能是未来抗病毒治疗的方向之一。 相似文献
12.
目的:程序性死亡分子-1(programmed death-1,PD-1)是近年来发现的属于B7/CD28家族的重要协同刺激分子,与其配体(programmed death -1 ligand,PD-L)结合后在调节T淋巴细胞的活化、分化及增殖功能方面起着重要作用。在慢性HBV感染不同阶段,PD-1表达水平存在差异,且与肝脏炎症程度、ALT及病毒载量等密切相关。通过不同途径阻断PD-1/PD-L1通路可以使耗竭的T淋巴细胞功能得到改善,提示可能是未来抗病毒治疗的方向之一。 相似文献
13.
目的研究补肾健脾方对ALT轻度异常的HBe Ag阳性慢性乙型肝炎(CHB)患者程序性死亡受体(PD)1/程序性死亡配体(PD-L)1表达的影响。方法选取2010年9月1日-2013年12月31日在上海中医药大学附属曙光医院就诊的32例ALT轻度升高的HBe Ag阳性CHB患者。在明确临床疗效的基础上,分离外周血单个核细胞,流式细胞仪检测补肾健脾方治疗前后患者外周血T淋巴细胞上PD-1和树突状细胞(DC)上PD-L1的表达变化。计量资料组间比较采用独立样本t检验,计数资料组间比较采用χ2检验。结果与治疗前相比,治疗组患者外周血CD4+T细胞表达PD-1百分率明显降低(P0.01),CD4+T细胞表达PD-1的平均荧光强度(MFI)显著下降(P0.05);治疗后两组患者CD4+T细胞表达PD-1百分率和MFI比较,差异均有统计学意义(P值均0.05)。治疗组CD8+T细胞表达PD-1百分率和MFI与治疗前相比均明显降低(P值均0.01);治疗后两组患者CD8+T细胞表达PD-1的MFI比较差异有统计学意义(P0.05)。与治疗前相比,治疗组DC表达PD-L1的MFI水平降低(P0.05),髓样树突状细胞(m DC)表达PD-L1的MFI亦明显降低(P0.01);治疗后两组患者比较DC和m DC的PD-L1表达水平,差异均无统计学意义(P值均0.05)。结论补肾健脾方治疗HBe Ag阳性的CHB患者能够显著降低外周血CD4+T、CD8+T细胞的PD-1的表达水平,降低DC和m DC的PD-L1表达水平,与其临床疗效有一定关系。 相似文献
14.
程序性死亡因子-1(programmed death 1,PD-1)是可以表达在T淋巴细胞膜表面的负向协同刺激分子受体,他与PD-1配体(programmeddeath 1 ligand,PD-L)形成通路后,可以减弱T淋巴细胞免疫反应,甚至导致T淋巴细胞功能衰竭.近来研究表明PD-I/PD-L通路的形成可以影响HBV... 相似文献
15.
目的:观察柴藿合剂联合替比夫定对HBeAg阳性慢性乙型肝炎(CHB)患者e抗原血清学转换的影响.方法:将90例CHB患者随机分为两组,对照组45例仅给予替比夫定治疗;治疗组45例应用柴藿合剂联合替比夫定治疗,疗程为2年.观察治疗1个月、3个月及2年时两组患者肝功能情况及2年时e抗原血清学转换情况.结果:治疗1个月时与对照组比较,治疗组患者肝功能显著改善(P<0.01);治疗3个月及2年时,治疗组患者HBV DNA水平明显降低,与对照组比较,差异有显著性意义(P<0.05);治疗2年时对照组患者e抗原血清学转换率为39.6%,治疗组为70.1%,两组比较差异有显著性意义(P<0.01).结论:柴藿合剂联合替比夫定是治疗CHB安全有效的方案,且联合用药可显著提高e抗原血清学转换率. 相似文献
16.
目的 通过比较慢性HBV感染免疫耐受期和免疫清除期的患者肝组织中程序性死亡分子-1及其配体的表达情况,探讨其与机体免疫功能状态的关系.方法 收集肝组织活体检查标本并分为免疫清除期组25例、免疫耐受期组19例,用免疫组织化学方法检测标本汇管区中T淋巴细胞程序性死亡分子-1及其配体的表达情况,通过半定量评分系统计算其占CD3阳性细胞的百分数,用t检验比较两组病例间程序性死亡分子-1及其配体表达的差异.结果 免疫耐受期组肝组织汇管区T淋巴细胞中程序性死亡分子-1所占CD3阳性细胞比率为63.79%±6.94%,高于免疫清除期的54.36%±10.08%,两组比较,t=3.492,P<0.01,差异有统计学意义;程序性死亡分子配体-1于T淋巴细胞中的表达在免疫耐受期组(66.47%±8.40%)中高于免疫清除期组(52.64%±6.20%),两组比较,t=6.288,P<0.01,差异有统计学意义.程序性死亡分子配体-1在枯否细胞中的表达强度及范围在两组间差异无统计学意义(P>0.05).结论 慢性HBV感染者肝组织中的程序性死亡分子-1及其配体表达水平的差异反映了免疫耐受期和免疫清除期的不同免疫功能状态. 相似文献
17.
目的:探讨慢性乙型肝炎(CHB)患者肝组织中程序性死亡分子-1(programmed death-1,PD-1)的表达与肝脏病理及中医辨证分型之间的关系。方法:对100例CHB患者均行肝组织穿刺术检查以明确肝组织病理分级和分期,采用免疫组织化学SP法检测肝组织中PD-1的表达,以同期住院的5例肝血管瘤患者为对照组,并对100例患者行中医辨证分型,研究肝组织中PD-1表达与肝脏病理及中医证型的关系。结果:CHB轻度、CHB中度、CHB重度各组患者肝内PD-1表达比较,差异有统计学意义(P〈0.05)。PD-1表达强度与肝组织炎症活动度及纤维化程度均呈正相关,相关系数分别为0.826(P〈0.001)和0.822(P〈0.001)。不同炎症、纤维化程度患者PD-1表达比较,差异均有统计学意义(P〈0.05)。肝脏病理分级、分期:肝郁脾虚型和湿热中阻型患者分布主要以G1-G2、S0-S2为主,两组间比较,差异无统计学意义(P〉0.05);瘀血阻络型的分布以G3-G4、S3-S4为主,与肝郁脾虚型、湿热中阻型比较,差异有统计学意义(P〈0.05)。不同中医证型的患者PD-1表达具有差异,瘀血阻络型最高,肝郁脾虚型最低;肝郁脾虚型与瘀血阻络型、湿热中阻型比较,差异有统计学意义(P〈0.01);偏实证组显著高于偏虚证组(P〈0.05)。结论:PD-1在不同病情程度CHB患者肝组织中表达水平不同,与肝组织炎症活动度及纤维化程度呈正相关,提示与CHB病情及慢性化机制有着密切关系,与不同中医证型也存在一定的相关性。检测肝脏内PD-1表达可为临床治疗、中医辨证分型提供一个新的方法与策略。 相似文献